https://allsci.com/news/regulatory/revtorpyk-pik3ca-breast-cancer-celcuity-seeks/ AllScien 2026-08-26T14:39:57.122167Z Celcuity seeks to expand Revtorpyk label to PIK3CA-mutant breast cancer after beating alpelisib https://allsci.com/news/regulatory/ck0803-fda-fast-track-als-cellenkoss-treg-cell/ AllScien 2026-08-26T14:32:26.133201Z Cellenkos's Treg cell therapy CK0803 wins FDA fast track for ALS https://allsci.com/news/approvals/rett-syndrome-treatment-european-commission/ AllScien 2026-08-26T14:28:02.967034Z EC approves Acadia's Daybu as first-ever Rett syndrome treatment in the EU https://allsci.com/news/first-in-human-trials/mwn110-obesity-trial-shanghai-minwei-launches/ AllScien 2026-08-26T13:14:26.695221Z Shanghai Minwei launches first human trial of ActRIIA/B antibody for obesity https://allsci.com/news/regulatory/pd-1il-15-fusion-protein-colorectal-cancer/ AllScien 2026-08-26T13:08:56.727841Z CSPC's PD-1/IL-15 fusion protein earns FDA Fast Track status for MSS/pMMR CRC https://allsci.com/news/approvals/orzeyful-narcolepsy-approval-takedas-becomes/ AllScien 2026-08-26T13:04:05.657983Z Takeda adds Japan approval for narcolepsy treatment Orzeyful https://allsci.com/news/approvals/trodelvy-pembrolizumab-tnbc-approval-ec-approves/ AllScien 2026-08-26T13:00:47.125670Z Trodelvy stakes out broader first-line TNBC role with EU combo approval https://allsci.com/news/clinical-trials/datroway-phase-iii-urothelial-cancer-plus/ AllScien 2026-08-26T12:27:43.157081Z AZ, Daiichi Sankyo take Datroway-rilvegostomig combo into Phase III bladder cancer trial https://allsci.com/news/clinical-trials/spy072-rheumatoid-arthritis-shows-statistically/ AllScien 2026-08-26T11:47:10.348653Z Spyre’s TL1A antibody hits RA endpoint but falls short in Phase II https://allsci.com/news/approvals/dolutegravir-newborn-hiv-fda-approves-for/ AllScien 2026-08-26T11:37:55.197685Z Viiv's dolutegravir nodded by FDA for HIV treatment in newborns https://allsci.com/news/clinical-trials/ivonescimab-biliary-tract-cancer-akesos-beats/ AllScien 2026-08-26T11:30:09.762054Z Akeso’s ivonescimab tops Imfinzi in fifth straight positive Phase III readout https://allsci.com/news/licensing-and-partnerships/sk-biopharmaceuticals-biohaven-acquisition/ AllScien 2026-08-26T11:19:26.322421Z SK Bio taps up Biohaven for Kv7 platform and epilepsy drug in USD 795m deal https://allsci.com/news/licensing-and-partnerships/viral-vector-manufacturing-4basebio-and-genezen/ AllScien 2026-08-26T10:59:36.603388Z 4basebio and Genezen integrate synthetic DNA platform into viral vector manufacturing workflow https://allsci.com/news/approvals/ziihera-fda-approval-her2-gastroesophageal-cancer/ AllScien 2026-08-25T16:27:49.037275Z Ziihera moves into first-line HER2+ gastroesophageal cancer with FDA approval https://allsci.com/news/clinical-trials/ivonescimab-nsclc-immunotherapy-becomes-first-to/ AllScien 2026-08-25T16:15:42.288902Z Ivonescimab Phase III PFS benefit gets peer-reviewed backing ahead of FDA decision https://allsci.com/news/licensing-and-partnerships/haisco-immunology-license-deal-licenses/ AllScien 2026-08-25T15:43:50.807572Z ARCH, Population Health launch Sentivera around Haisco immunology asset in USD 1.5b deal https://allsci.com/news/funding/hdac-inhibitors-cardiometabolic-disease/ AllScien 2026-08-25T15:32:35.786429Z Revier launches with EUR 6m bet on selective HDAC inhibition https://allsci.com/news/funding/zelpultide-alfa-bronchopulmonary-dysplasia/ AllScien 2026-08-25T15:24:59.759764Z Airway Therapeutics raises USD 50m to advance late-stage zelpultide alfa trial in BPD https://allsci.com/news/regulatory/arimoclomol-niemann-pick-disease-rejects-for-type/ AllScien 2026-08-25T15:07:41.898158Z EMA rejects arimoclomol for Niemann-Pick disease type C over efficacy concerns https://allsci.com/news/regulatory/rsv-vaccine-fda-approval-cspcs-clears-for-us/ AllScien 2026-08-25T15:00:22.748450Z CSPC's RSV vaccine clears FDA for US trials weeks after China approval https://allsci.com/news/clinical-trials/bb-025-reversal-agent-stroke-baskings-achieves/ AllScien 2026-08-25T14:55:59.171479Z Basking's BB-025 rapidly reverses stroke thrombolytic in Phase I study https://allsci.com/news/grants/machine-learning-drug-testing-uc-irvine-receives/ AllScien 2026-08-25T14:46:34.621592Z UC Irvine takes AI-powered metabolic imaging into drug resistance testing https://allsci.com/news/clinical-trials/rhinovirus-vaccine-apollos-pan-rhinovirus/ AllScien 2026-08-25T14:43:47.838597Z Apollo's pan-rhinovirus vaccine triggers cross-species T cell responses in Phase I trial https://allsci.com/news/research/cdk8-inhibition-osteoarthritis-reduces-cartilage/ AllScien 2026-08-25T13:53:06.941732Z CDK8 emerges as potential disease-modifying target in osteoarthritis https://allsci.com/news/research/ulk3-multiple-myeloma-moffitt-researchers/ AllScien 2026-08-25T13:30:10.488031Z Moffitt researchers identify ULK3 dependency in multiple myeloma, report preclinical inhibitor efficacy https://allsci.com/news/research/autonomous-protein-binder-design-anthropics/ AllScien 2026-08-25T12:57:52.983689Z Anthropic's Claude autonomously designs protein binders against 14 of 15 targets https://allsci.com/news/approvals/brinsupri-bronchiectasis-approval-japan-approves/ AllScien 2026-08-25T11:13:53.004658Z Japan approves Brinsupri as first treatment for non-cystic fibrosis bronchiectasis https://allsci.com/news/approvals/hypothalamic-obesity-treatment-japan-rhythms/ AllScien 2026-08-25T11:13:30.643941Z Rhythm's Imcivree becomes first approved therapy for acquired hypothalamic obesity in Japan https://allsci.com/news/clinical-trials/asp2138-phase-iii-gastric-cancer-astellas/ AllScien 2026-08-25T11:12:49.691333Z Astellas pushes CLDN18.2 bispecific ASP2138 into Phase III https://allsci.com/news/first-in-human-trials/atg-201-clinical-trial-australia-antengenes/ AllScien 2026-08-25T11:09:48.338644Z Antengene preps UCB-partnered CD19 bispecific TCE for first-in-human autoimmune testing in Oz https://allsci.com/news/regulatory/fda-priority-review-jemperli-rectal-cancer/ AllScien 2026-08-25T11:08:16.493874Z FDA puts GSK’s Jemperli on priority review in locally advanced rectal cancer https://allsci.com/news/approvals/hibsago-hepatitis-b-cure-japan-approves-as-first/ AllScien 2026-08-25T11:03:58.691905Z Japan approves GSK's Hibsago as first functional cure for chronic hepatitis B https://allsci.com/news/clinical-trials/pfizer-autoimmune-clinical-trial-opens-phase-of/ AllScien 2026-08-25T07:59:07.007742Z Pfizer tests undisclosed immune-modulating asset across four autoimmune diseases https://allsci.com/news/approvals/imaavy-warm-autoimmune-hemolytic-anemia/ AllScien 2026-08-25T07:48:19.654788Z FDA approves Imaavy as first treatment specifically indicated for wAIHA https://allsci.com/news/research/cb2r-breast-cancer-plasticity-ucm-and-mit/ AllScien 2026-08-24T16:26:40.782816Z UCM and MIT research shows transient CB2R modulation locks breast cancer cells into less aggressive state https://allsci.com/news/clinical-trials/pancreatic-cancer-cxcr4-trial-columbia-led/ AllScien 2026-08-24T16:23:36.995535Z Columbia-led trial reports 64% response rate in small Phase II for four-drug CXCR4 regimen https://allsci.com/news/regulatory/rgx-121-fda-clinical-hold-on-stalls-regenxbios/ AllScien 2026-08-24T15:31:26.652289Z Spinal MRI findings trigger FDA hold, derail RegenxBio’s RGX-121 filing